In today’s evolving pharmaceutical environment, the fill‐finish segment stands out as a critical linchpin connecting drug ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available.

We're now just over a month away from Nintendo Switch 2 pre-orders potentially hitting the shelves. Nintendo's hardware-focused Direct event is still scheduled for April 2, and if previous ...

In other Lilly news, the FDA recently approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. The drug is is now approved in the United States ...

The Global Prefilled Syringes Market was valued at $5.43 billion in 2022 and is projected to reach $10.59 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.70% during the forecast ...

The 10th annual Pre-Filled Syringes East Coast conference will once again play host to an international audience of drug delivery, medical device and PFS experts to discuss emerging trends and ...

Tablet shows same established efficacy and safety as the Evrysdi oral solution. HealthDay News — The U.S. Food and Drug Administration has approved a new drug application for a tablet version of ...

But Eli Lilly isn’t stopping there. They’re leading an ambitious charge with their new star, Omvoh, proving effective for patients with stubborn cases of Crohn’s disease. This drug achieved notable ...

GlobalData is the parent company of Clinical Trials Arena. In terms of competition, there are currently only two other IL-23 inhibitors approved in the US besides Tremfya – Eli Lilly’s Omvoh ...